vs
UiPath, Inc.（PATH）とPrestige Consumer Healthcare Inc.（PBH）の財務データ比較。上の社名をクリックして会社を切り替えられます
UiPath, Inc.の直近四半期売上が大きい（$411.1M vs $283.4M、Prestige Consumer Healthcare Inc.の約1.5倍）。UiPath, Inc.の純利益率が高く（48.4% vs 16.5%、差は31.9%）。UiPath, Inc.の前年同期比売上増加率が高い（15.9% vs -2.4%）。Prestige Consumer Healthcare Inc.の直近四半期フリーキャッシュフローが多い（$75.3M vs $25.1M）。過去8四半期でPrestige Consumer Healthcare Inc.の売上複合成長率が高い（1.2% vs 0.7%）
UiPath Inc.は人工知能（AI）、自律型オートメーションおよびオーケストレーションソフトウェアを開発するグローバルソフトウェア企業です。同社の製品は複雑な業務プロセスやワークフローを自動化するAIエージェントの構築・管理に対応し、各業界の業務効率向上を支援しています。
プレステージ・コンシューマー・ヘルスケア社はアメリカの企業で、一般用医薬品のヘルスケア製品および家庭用洗浄製品の販売・流通を手がけています。1996年にMedtech Products社、Prestige Brands International社、Spic and Span社の合併により設立され、本社はニューヨーク州タリータウン、バージニア州リンチバーグに製造工場を構えています。
PATH vs PBH — 直接比較
損益計算書 — Q3 FY2026 vs Q3 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $411.1M | $283.4M |
| 純利益 | $198.8M | $46.7M |
| 粗利率 | 83.3% | 55.5% |
| 営業利益率 | 3.2% | 29.1% |
| 純利益率 | 48.4% | 16.5% |
| 売上前年比 | 15.9% | -2.4% |
| 純利益前年比 | 1966.2% | -23.5% |
| EPS（希薄化後） | $0.37 | $0.97 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $411.1M | $283.4M | ||
| Q3 25 | $361.7M | $274.1M | ||
| Q2 25 | $356.6M | $249.5M | ||
| Q1 25 | $423.6M | $296.5M | ||
| Q4 24 | $354.7M | $290.3M | ||
| Q3 24 | $316.3M | $283.8M | ||
| Q2 24 | $335.1M | $267.1M | ||
| Q1 24 | $405.3M | $277.0M |
| Q4 25 | $198.8M | $46.7M | ||
| Q3 25 | $1.6M | $42.2M | ||
| Q2 25 | $-22.6M | $47.5M | ||
| Q1 25 | $51.8M | $50.1M | ||
| Q4 24 | $-10.7M | $61.0M | ||
| Q3 24 | $-86.1M | $54.4M | ||
| Q2 24 | $-28.7M | $49.1M | ||
| Q1 24 | $33.9M | $49.5M |
| Q4 25 | 83.3% | 55.5% | ||
| Q3 25 | 82.2% | 55.3% | ||
| Q2 25 | 82.1% | 56.2% | ||
| Q1 25 | 84.8% | 57.3% | ||
| Q4 24 | 82.0% | 55.5% | ||
| Q3 24 | 80.0% | 55.5% | ||
| Q2 24 | 83.5% | 54.7% | ||
| Q1 24 | 86.8% | 54.8% |
| Q4 25 | 3.2% | 29.1% | ||
| Q3 25 | -5.6% | 29.1% | ||
| Q2 25 | -4.6% | 28.8% | ||
| Q1 25 | 7.9% | 29.8% | ||
| Q4 24 | -12.2% | 31.7% | ||
| Q3 24 | -32.7% | 29.7% | ||
| Q2 24 | -14.8% | 27.0% | ||
| Q1 24 | 3.7% | 29.7% |
| Q4 25 | 48.4% | 16.5% | ||
| Q3 25 | 0.4% | 15.4% | ||
| Q2 25 | -6.3% | 19.0% | ||
| Q1 25 | 12.2% | 16.9% | ||
| Q4 24 | -3.0% | 21.0% | ||
| Q3 24 | -27.2% | 19.2% | ||
| Q2 24 | -8.6% | 18.4% | ||
| Q1 24 | 8.4% | 17.9% |
| Q4 25 | $0.37 | $0.97 | ||
| Q3 25 | $0.00 | $0.86 | ||
| Q2 25 | $-0.04 | $0.95 | ||
| Q1 25 | $0.09 | $1.00 | ||
| Q4 24 | $-0.02 | $1.22 | ||
| Q3 24 | $-0.15 | $1.09 | ||
| Q2 24 | $-0.05 | $0.98 | ||
| Q1 24 | $0.07 | $0.98 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $1.4B | $62.4M |
| 総負債低いほど良い | — | $1.0B |
| 株主資本純資産 | $1.9B | $1.8B |
| 総資産 | $2.9B | $3.5B |
| 負債/資本比率低いほどレバレッジが低い | — | 0.56× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $1.4B | $62.4M | ||
| Q3 25 | $1.4B | $119.1M | ||
| Q2 25 | $1.6B | $139.5M | ||
| Q1 25 | $1.6B | $97.9M | ||
| Q4 24 | $1.6B | $50.9M | ||
| Q3 24 | $1.7B | $51.5M | ||
| Q2 24 | $1.9B | $34.3M | ||
| Q1 24 | $1.9B | $46.5M |
| Q4 25 | — | $1.0B | ||
| Q3 25 | — | $993.1M | ||
| Q2 25 | — | $992.7M | ||
| Q1 25 | — | $992.4M | ||
| Q4 24 | — | $992.0M | ||
| Q3 24 | — | $1.1B | ||
| Q2 24 | — | $1.1B | ||
| Q1 24 | — | $1.1B |
| Q4 25 | $1.9B | $1.8B | ||
| Q3 25 | $1.7B | $1.8B | ||
| Q2 25 | $1.7B | $1.9B | ||
| Q1 25 | $1.8B | $1.8B | ||
| Q4 24 | $1.7B | $1.8B | ||
| Q3 24 | $1.8B | $1.7B | ||
| Q2 24 | $2.0B | $1.7B | ||
| Q1 24 | $2.0B | $1.7B |
| Q4 25 | $2.9B | $3.5B | ||
| Q3 25 | $2.6B | $3.4B | ||
| Q2 25 | $2.6B | $3.4B | ||
| Q1 25 | $2.9B | $3.4B | ||
| Q4 24 | $2.7B | $3.3B | ||
| Q3 24 | $2.7B | $3.3B | ||
| Q2 24 | $2.8B | $3.3B | ||
| Q1 24 | $3.0B | $3.3B |
| Q4 25 | — | 0.56× | ||
| Q3 25 | — | 0.54× | ||
| Q2 25 | — | 0.54× | ||
| Q1 25 | — | 0.54× | ||
| Q4 24 | — | 0.55× | ||
| Q3 24 | — | 0.61× | ||
| Q2 24 | — | 0.65× | ||
| Q1 24 | — | 0.68× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $28.3M | $78.3M |
| フリーキャッシュフロー営業CF - 設備投資 | $25.1M | $75.3M |
| FCFマージンFCF / 売上 | 6.1% | 26.6% |
| 設備投資強度設備投資 / 売上 | 0.8% | 1.1% |
| キャッシュ転換率営業CF / 純利益 | 0.14× | 1.68× |
| 直近12ヶ月FCF直近4四半期 | — | $267.2M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $28.3M | $78.3M | ||
| Q3 25 | $41.6M | $57.5M | ||
| Q2 25 | $119.0M | $79.0M | ||
| Q1 25 | $146.1M | $61.8M | ||
| Q4 24 | $28.1M | $65.1M | ||
| Q3 24 | $46.4M | $69.8M | ||
| Q2 24 | $100.0M | $54.8M | ||
| Q1 24 | $145.6M | $66.9M |
| Q4 25 | $25.1M | $75.3M | ||
| Q3 25 | — | $55.4M | ||
| Q2 25 | $106.2M | $78.2M | ||
| Q1 25 | $138.7M | $58.4M | ||
| Q4 24 | $23.2M | $63.5M | ||
| Q3 24 | $45.0M | $67.8M | ||
| Q2 24 | $98.8M | $53.6M | ||
| Q1 24 | $141.8M | $63.8M |
| Q4 25 | 6.1% | 26.6% | ||
| Q3 25 | — | 20.2% | ||
| Q2 25 | 29.8% | 31.3% | ||
| Q1 25 | 32.7% | 19.7% | ||
| Q4 24 | 6.5% | 21.9% | ||
| Q3 24 | 14.2% | 23.9% | ||
| Q2 24 | 29.5% | 20.1% | ||
| Q1 24 | 35.0% | 23.0% |
| Q4 25 | 0.8% | 1.1% | ||
| Q3 25 | 0.0% | 0.8% | ||
| Q2 25 | 3.6% | 0.3% | ||
| Q1 25 | 1.7% | 1.2% | ||
| Q4 24 | 1.4% | 0.5% | ||
| Q3 24 | 0.4% | 0.7% | ||
| Q2 24 | 0.4% | 0.4% | ||
| Q1 24 | 0.9% | 1.1% |
| Q4 25 | 0.14× | 1.68× | ||
| Q3 25 | 26.25× | 1.36× | ||
| Q2 25 | — | 1.66× | ||
| Q1 25 | 2.82× | 1.23× | ||
| Q4 24 | — | 1.07× | ||
| Q3 24 | — | 1.28× | ||
| Q2 24 | — | 1.12× | ||
| Q1 24 | 4.29× | 1.35× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
PATH
| Subscription Services | $247.6M | 60% |
| License | $150.0M | 36% |
| Professional Services And Other | $13.5M | 3% |
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
